Retrospective Analysis of Testicular Germ Cell Tumor Patients with Brain Metastases: A Single-Center Experience
Journal of Oncological Science, cilt.8, sa.1, ss.27-33, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 8 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.37047/jos.2021-87403
- Dergi Adı: Journal of Oncological Science
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.27-33
- Anahtar Kelimeler: Central nervous system neoplasms, Testicular germ cell tumor, Testicular neoplasms
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: We evaluated the survival characteristics of testicular germ cell tumor (GCT) patients with brain metastases (BM). Material and Methods: In this retrospective cross-sectional study, patients with relapsed or refractory GCT and BM were evaluated. The char¬acteristic clinical features of the patients, their systemic treatments, local treatments applied to BM, and follow-up periods were recorded. The primary endpoint was to assess survival after detection of synchronous and metachronous BM. The secondary endpoint was determined as over¬all survival (OS). Results: Twenty-five patients were included in this study with median age and interquartile range (IQR) of 30.24 and 7.92, respectively. Stage IIIC was detected at first diagnosis in 72% of the patients. The most commonly used local BM treatment was the combi¬nation of surgery and radiotherapy (60%). The objective response rate (complete response plus partial response) after local BM treatment was 60%. The median OS in the whole group was 24.75 (IQR: 25.97) months. The median OS (IQR) in the synchronous BM group was signifi¬cantly different than that in the metachronous BM group [33.51 (18.13) vs. 9.97 (7.52), 95% confidence interval of 6.7 to 40.3 months, p=0.013]. There was no difference in the median OS between the groups [median (IQR)=36.39 (25.35) months vs. 23.70 (35.68) months, p=0.672]. Conclusion: The patients with GCTs presenting with BM during diagnosis were in a better condition than those who developed BM at relapse. However, no significant difference was found in OS. This may indicate shorter survival times for the patients who relapse, as the tumor is resistant to systemic therapy.